Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Highlights PART 05: Global pharmaceutical market • Market size and forecast PART 06: Road to pharmerging markets PART 07: Pharmerging markets PART 08: Market landscape • Medicine spending in emerging economies • Five forces analysis PART 09: Market segmentation by geography PART 10: Market overview of tier I countries • China PART 11: Market overview of tier II countries • Brazil • Russia • India PART 12: Market overview of tier III countries • Market size and forecast PART 13: Market drivers • Limitations in developed economies fuels demand in emerging economies • Increasing focus toward biosimilar in potential areas • Expansion initiatives of vendors PART 14: Impact of drivers PART 15: Market challenges • IP protection issues • Socio-political issues in cross geography transactions • Stringent price control and generic-centric usage lead to value erosion PART 16: Impact of drivers and challenges PART 17: Market trends • Potential of new countries in emerging markets • Positive outlook toward adoption of targeted therapies • Evolving stakeholder landscape to change market dynamics PART 18: Vendor landscape • Competitive scenario PART 19: Key vendor analysis • AstraZeneca • GlaxoSmithKline • Pfizer • Sanofi • Novartis • Other prominent vendors PART 20: Appendix • List of Abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Global country rankings in pharmaceutical market based on healthcare spending Exhibit 02: Global pharmaceutical market 2016-2021 ($ trillions) Exhibit 03: Drivers, challenges and trends of global pharmaceutical market Exhibit 04: Growth comparision between developed markets and pharmerging markets Exhibit 05: Share of pharmerging markets in global pharmaceutical market, 2016 Exhibit 06: Snapshot of key pharmerging markets Exhibit 07: Regulatory landscape in key pharmerging markets Exhibit 08: Pharmerging markets 2016-2021 ($ billions) Exhibit 09: Comparison of medicine spending in developed economies and pharmerging markets Exhibit 10: Medicine spending and growth rates in pharmerging markets Exhibit 11: Standard units in 2021 by product type in pharmerging countries Exhibit 12: Expected medicine spending by geography Exhibit 13: Volume growth and population with more than $5,000/year income by country 2016 Exhibit 14: Percentage share of pharmerging markets in global pharmaceutical market 2016-2021 Exhibit 15: Percentage share of tier I, II and III countries in total pharmerging markets 2016-2021 Exhibit 16: Pharmerging markets share by country, 2016 Exhibit 17: Five forces analysis Exhibit 18: Pharmerging markets segment by geography Exhibit 19: Geographic representation of tier I country Exhibit 20: China GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP) Exhibit 21: On-going healthcare reforms in China Exhibit 22: Segmentation of Chinese pharmaceutical market Exhibit 23: Segment analysis in Chinese pharmaceutical market Exhibit 24: Regulatory bodies Exhibit 25: Major therapy areas based on sales of drugs, 2016 Exhibit 26: Major acquisitions in Chinese pharmaceutical market 2014-2016 Exhibit 27: Drivers and challenges in Chinese pharmaceutical market Exhibit 28: Pharmaceutical market in China 2016-2021 ($ billions) Exhibit 29: China pharmaceutical market: SWOT analysis Exhibit 30: Geographic representation of tier II countries Exhibit 31: Pharmaceutical market in tier II countries 2016-2021 ($ billions) Exhibit 32: Brazil GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP) Exhibit 33: Regulatory bodies Exhibit 34: Segmentation of pharmaceutical market in Brazil 2016 Exhibit 35: Major acquisitions in Brazil pharmaceutical market Exhibit 36: Drivers and challenges in Brazilian pharmaceutical market Exhibit 37: Pharmaceutical market in Brazil 2016-2021 ($ billions) Exhibit 38: Brazil pharmaceutical market: SWOT analysis Exhibit 39: Russia GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP) Exhibit 40: Major acquisitions in Russian pharmaceutical market Exhibit 41: Drivers and challenges in Russian pharmaceutical market Exhibit 42: Pharmaceutical market in Russia 2016-2021 ($ billions) Exhibit 43: Russia pharmaceutical market: SWOT analysis Exhibit 44: India GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP) Exhibit 45: Regulatory landscape Exhibit 46: Major acquisitions in pharmaceutical sector in India Exhibit 47: Drivers and challenges in Indian pharmaceutical market Exhibit 48: Pharmaceutical market in India 2016-2021 ($ billions) Exhibit 49: India pharmaceutical market: SWOT analysis Exhibit 50: Geographic representation of tier III countries Exhibit 51: Pharmaceutical market in tier III countries 2016-2021 ($ billions) Exhibit 52: Revenues from pharmaceuticals for few of the tier III countries 2016 ($ billions) Exhibit 53: Snapshot of key countries in tier III countries Exhibit 54: Tier III countries pharmaceutical market: SWOT analysis Exhibit 55: Factors that are driving the growth in emerging economies Exhibit 56: Biosimilar development in emerging economies Exhibit 57: Few acquisitions and their impact Exhibit 58: Impact of drivers Exhibit 59: Impact of drivers and challenges Exhibit 60: Positioning of key vendors in pharmerging markets 2015 Exhibit 61: Competitive analysis snapshot Exhibit 62: Top selling products in emerging markets 2015 Exhibit 63: Key takeaways Exhibit 64: Key highlights in emerging markets Exhibit 65: AstraZeneca strength assessment Exhibit 66: Geographic segmentation by revenue 2015 Exhibit 67: Key takeaways Exhibit 68: Key highlights in emerging markets Exhibit 69: GSK strength assessment Exhibit 70: Geographic segmentation by revenue 2015 Exhibit 71: Key takeaways Exhibit 72: Pfizer: YoY and growth rate in emerging markets Exhibit 73: Segmentation by revenue in emerging markets ($ millions) Exhibit 74: Key highlights in emerging markets Exhibit 75: Pfizer strength assessment Exhibit 76: Pfizer: Geographical segmentation by revenue 2015 Exhibit 77: Top selling products0 Exhibit 78: Key emerging products0 Exhibit 79: Geographical segmentation by revenue1 Exhibit 80: Key takeaways2 Exhibit 81: Key highlights in emerging markets2 Exhibit 82: Sanofi strength assessment3 Exhibit 83: Key takeaways4 Exhibit 84: Key highlights in emerging markets5 Exhibit 85: Novartis strength assessment6 Exhibit 86: Novartis: Geographical segmentation by revenue 20156

AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, Novartis, Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, Valeant Pharmaceuticals.